The aims of this study are to describe the characteristics of clinical trials in glomerulonephritis listed in ClinicalTrials.gov and examine trends in study design, trial phases, location of trial, funding sources, and primary purpose in the last 10 years. A survey was conducted of ongoing clinical trials in glomerulonephritis registered in the ClinicalTrials.gov website using the advanced search option from 1/1/2008 to 12/31/2017. All trials with the search words were included except observational studies. Almost 59% of the trials were randomized, 11% were quadruple-masked, 9.6% were doublemasked, and 3.4% were triple-masked. Of the 352 eligible trials, 26.7% were phase 3 trials, 19% were phase 4, 32.3% were phase 2, and 8.2% were phase 1. Of the trials, 21% were multinational and 42% were multicenter studies. The average number of participants in all the trials was 80. Funding data have shown that industry and other funding sources have contributed more towards glomerulonephritis trials when compared to federal agencies. The primary purpose of majority of the trials was treatment (92%). Preventive trials were only 11, basic sciences 6, and diagnostic 4. The year 2017 had the most number of trials which is very promising. The majority of trials were randomized and focused on treatment is very reassuring. The fact that there were more trials funded by industry and university rather than federal agencies is concerning.
Introduction
Nephrology has the lowest number of clinical trials among other specialties of internal medicine. Glomerulonephritis had the lowest number of clinical trials when compared to others such as urinary tract infection, diabetic nephropathy, and transplantation [1] . Several reasons have led to the lack of clinical trials in glomerulonephritis. The low occurrence of the disease makes it difficult to recruit patients for different studies. The lack of a standardized approach for glomerulonephritis management also makes large multicenter trials difficult to conduct. The high cost of trials can lead to a lack of collaboration. Each glomerulonephritis subtype can have different definitions and endpoints [2] . A study done in 2002 showed that the majority of the trials were non-RCT and did not focus on interventional questions [1] . The lack of valid biomarkers and kidney-specific drug development tools have also contributed to this dearth [3] .
Aim
To analyze the trends in clinical trials in glomerulonephritis in the last 10 years, give a brief description of their phases, study designs, and suggest key areas for conducting high-quality trials in glomerulonephritis. Table 1 illustrates that the majority of the GN clinical trials are in phase II (n = 114). Ninety-four trials are in phase III and 67 in phase IV. Of the trials, 57.9% were conducted outside the USA, 13.6% were conducted within the USA, and 21% had locations both in the USA and outside. Only 4% of the trials had more than 300 subjects enrolled in their studies. The average number of participants in all the trials was 80. 32.6% of the trials were completed, 24.4% are recruiting, and 11.3% of them are active
but not yet recruiting. The primary purpose of a majority of the trials was treatment (92%). Preventive trials were only 11, basic sciences 6, and diagnostic 4.
Discussion
This study using the ClinicalTrials.gov website in 2018 suggests that the majority of all ongoing clinical trials in glomerulonephritis were randomized (59%), open-label (72%), phase II trials (32%), focused on treatment, and being funded by industry with about 42% being multicenter studies.
Results showed that 59% of the trials were randomized, 11% of the trials were quadruple-masked, 9.6% were double-masked, and 3.4% were triple-masked (. Table 1 ). Seven of the randomized trials were crossover studies. The parallel group randomized control design is the most common design method used in these trials. Adaptive trial designs are being widely accepted in clinical trials. An adaptive trial is a design in which changes can be made after the start of the trial without affecting its validity [4] . These can increase the efficiency Fig. 1 Number of trials [2008] [2009] [2010] [2011] [2012] [2013] [2014] [2015] [2016] [2017] of randomized clinical trials, reduce cost, and enhance the potential of finding a true benefit. [5] The majority of clinical trials were in phase II. There has been a steady rise in the number of phase II and III trials over the last 10-year period. The year 2015 saw a sharp rise in the number of phase IV trials. There has been an increase in phase II, III, and IV trials in the last year. Positive outcomes are more expected in later phase when compared to early phase as the drug's safety and efficacy have already been proved [6] . The later phase trials were funded more by hospital/university as compared to industry or government. Funding data have shown that industry and other funding sources have contributed more towards glomerulonephritis trials compared to federal agencies. Research funded by industries is more likely to favor the drug made by the industry rather than other drugs funded by other sources [7] . Kidney research has been receiving less funding from NIH as compared to other diseases [8] . Multicenter collaboration facilitates a larger sample size and provides sufficient statistical power to detect smaller treatment effects [9] . Of the trials, 21% were multinational and 42% were multicenter studies. Only 4% of the trials had more than 300 subjects enrolled in their studies.
Overcoming adversities for lack of clinical trials in glomerulonephritis has been a major challenge faced by researchers over the years. The low prevalence in glomerular diseases requires multicenter collaboration across institutions and nations which can help in recruiting more patients for the trials. Creating more registries and merging multiple small registries can help in this collaboration. Use of a single IRB to facilitate multisite involvement can be beneficial [10] . Electronic health records make research faster, enroll more patients, and can make better quality trials with fewer resources [11] . Adaptive designs can be used as it allows for changes to be *Others-university/hospital made in the trial design in response to accumulating information and improves efficiency. Investigators and clinicians should be encouraged to agree on common classification systems of disease and common clinical endpoints. Assessing outcomes that are clinically important can limit the costs and strengthen the trial designs. Nephrologists should be trained to have expertise in the design and implementation of clinical trials [12] . A minimum set of outcomes should be established that has to be reported in all clinical trials called core outcome sets [13] . These steps offer a hope to conduct high-quality clinical trials in glomerulonephritis that will lead to more effective therapies for the patient population. This study focused on the trends in glomerulonephritis clinical trials and provided important data that enables future monitoring of research in glomerulonephritis. The fact that the rise in the number of trials in the last year and that the majority of trials were randomized and focussed on treatment is very promising. However, there were more trials funded by industry and university rather than federal agencies is concerning. The clinicaltrials.gov website is a very useful tool to study these trends which can help investigators to get a better picture of ongoing trials and make necessary changes.
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